Skip to main content
Top
Published in: Inflammation 3/2009

01-06-2009

The Profile of Prostate Epithelial Cytokines and its Impact on Sera Prostate Specific Antigen Levels

Authors: Yosra Bouraoui Mechergui, Awatef Ben Jemaa, Chekib Mezigh, Benito Fraile, Nawfel Ben Rais, Ricardo Paniagua, Mar Royuela, Ridha Oueslati

Published in: Inflammation | Issue 3/2009

Login to get access

Abstract

The aim of this study was determined the expression of pro inflammatory cytokines in prostate epithelial cells. Furthermore, we analysed the relation between these cytokines and sera PSA levels according the three groups: 0–4, 4–20 and >20 ng/mL. The study was carried out in five normal prostate (NP), 27 benign prostate hyperplastic (BPH) and 18 prostate cancer (PC). Immunohistochemical and Western blot analysis was performed. Serum levels of PSA were assayed by Immulite autoanalyser. The western Blotting analysis revealed an immunoexpression of IL-1α, IL-6 and TNFα in BPH and PC. IL-1α, was absent in NP. Immunohistochemical analysis showed significant high optical density to IL-1α and IL-6 in cancer epithelial cells (19.45 ± 3.25 and 26.2 ± 3.19) compared to normal cells (1.73 ± 1.51 and 4.83 ± 2.65). While, TNFα optical densities were not significant in NP (12.03 ± 2.9), BPH (9.87 ± 3.85) and PC (13.34 ± 2.34). The different profiles of cytokines according sera PSA levels showed a high immunoexpression of the profile (IL-6+, IL-1α+) in BPH patients with PSA between 0–4 and 4–20 ng/mL. However, PC patients with sera PSA between 4 and 20 ng/mL, showed a significant high immunoexpression of the profile (IL-6+, IL-1α−). This data demonstrate a locally production of pro-inflammatory cytokines by prostate epithelial cells and a cross talk between PSA and these cytokines in prostate pathologies.
Literature
3.
go back to reference De Marzo, A. M., T. L. DeWeese, E. A. Platz, et al. 2004. Pathological and mechanisms of prostate carcinogenesis: Implication for diagnosis, detection, prevention and treatment. J. Cell Biochem. 91:459–477. doi:10.1002/jcb.10747.PubMedCrossRef De Marzo, A. M., T. L. DeWeese, E. A. Platz, et al. 2004. Pathological and mechanisms of prostate carcinogenesis: Implication for diagnosis, detection, prevention and treatment. J. Cell Biochem. 91:459–477. doi:10.​1002/​jcb.​10747.PubMedCrossRef
4.
go back to reference Panja, A., S. Goldberg, L. Eckmann, et al. 1998. The regulation and functional consequence of pro-inflammatory cytokine binding on human intestinal epithelial cells. J. Immunol. 161:3675–3684.PubMed Panja, A., S. Goldberg, L. Eckmann, et al. 1998. The regulation and functional consequence of pro-inflammatory cytokine binding on human intestinal epithelial cells. J. Immunol. 161:3675–3684.PubMed
6.
go back to reference Borger, P., G. H. Koeter, J. A. Timmerman, et al. 1999. Proteases from Aspergillus fumugatus induce interleukin (IL)-6 and IL-8 profuction in airway epithelial cell lines by transcriptional mechanisms. J. Infect. Dis. 180:1267–1274. doi:10.1086/315027.PubMedCrossRef Borger, P., G. H. Koeter, J. A. Timmerman, et al. 1999. Proteases from Aspergillus fumugatus induce interleukin (IL)-6 and IL-8 profuction in airway epithelial cell lines by transcriptional mechanisms. J. Infect. Dis. 180:1267–1274. doi:10.​1086/​315027.PubMedCrossRef
7.
go back to reference Ricote, M., I. Garcia-Tuñon, F. R. Bethencourt, et al. 2004. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 100:1388–1396. doi:10.1002/cncr.20142.PubMedCrossRef Ricote, M., I. Garcia-Tuñon, F. R. Bethencourt, et al. 2004. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 100:1388–1396. doi:10.​1002/​cncr.​20142.PubMedCrossRef
11.
go back to reference Lee, S. O., W. Lou, M. Hou, et al. 2003. Interleukin-4 enhances prostate specific antigen expression by activation of the androgen receptor and AKT pathway. Oncogene 22:6037–6044. Lee, S. O., W. Lou, M. Hou, et al. 2003. Interleukin-4 enhances prostate specific antigen expression by activation of the androgen receptor and AKT pathway. Oncogene 22:6037–6044.
12.
go back to reference Lee, S. O., W. Lou, M. Hou, et al. 2003. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin. Cancer Res. 9:370–376.PubMed Lee, S. O., W. Lou, M. Hou, et al. 2003. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin. Cancer Res. 9:370–376.PubMed
15.
go back to reference Lieberman, R. 2004. Evidence-based medical perspectives: The evolving role of PSA for early detection, monitoring of treatment response and as a surrogate end point of efficacy for interventions in men with different clinical states for the prevention and progression of prostate cancer. Am. J. Ther. 11:501–506. doi:10.1097/01.mjt.0000141604.20320.0c.PubMedCrossRef Lieberman, R. 2004. Evidence-based medical perspectives: The evolving role of PSA for early detection, monitoring of treatment response and as a surrogate end point of efficacy for interventions in men with different clinical states for the prevention and progression of prostate cancer. Am. J. Ther. 11:501–506. doi:10.​1097/​01.​mjt.​0000141604.​20320.​0c.PubMedCrossRef
16.
go back to reference Catalona, W. J., A. W. Partin, K. M. Slawin, et al. 1998. Use the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 297:1542–1547. doi:10.1001/jama.279.19.1542.CrossRef Catalona, W. J., A. W. Partin, K. M. Slawin, et al. 1998. Use the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 297:1542–1547. doi:10.​1001/​jama.​279.​19.​1542.CrossRef
18.
go back to reference Michalaki, V., K. Syrigos, P. Charles, et al. 2004. Serum levels of IL-6 and TNFα correlate with clinicopathological features and patients survival in patients with prostate cancer. Br. J. Cancer 90:2312–2316.PubMed Michalaki, V., K. Syrigos, P. Charles, et al. 2004. Serum levels of IL-6 and TNFα correlate with clinicopathological features and patients survival in patients with prostate cancer. Br. J. Cancer 90:2312–2316.PubMed
28.
go back to reference Anim, J. T., C. Udo, and B. John. 1998. Characterisation of inflammatory cells in benign prostatic hyperplasia. BJU Int. 84:976–978. Anim, J. T., C. Udo, and B. John. 1998. Characterisation of inflammatory cells in benign prostatic hyperplasia. BJU Int. 84:976–978.
29.
go back to reference Dinarello, C. A. 1996. Biologic basis for interleukin-1 in disease. Blood 87:2095.PubMed Dinarello, C. A. 1996. Biologic basis for interleukin-1 in disease. Blood 87:2095.PubMed
30.
31.
go back to reference Nakashima, J., M. Tachibana, Y. Horiguchi, et al. 2000. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res. 6:2702–2706.PubMed Nakashima, J., M. Tachibana, Y. Horiguchi, et al. 2000. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res. 6:2702–2706.PubMed
34.
go back to reference Luderer, A. A., Y. T. Chen, T. F. Soriano, et al. 1995. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46:187–194. doi:10.1016/S0090-4295(99)80192-7.PubMedCrossRef Luderer, A. A., Y. T. Chen, T. F. Soriano, et al. 1995. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46:187–194. doi:10.​1016/​S0090-4295(99)80192-7.PubMedCrossRef
35.
go back to reference Bouraoui, Y., N. Ben Rais, Z. Elouni, et al. 2006. Evolution’s molecular forms of Prostate-Specific-Antigen in serological groups of patients with prostatic pathologies. Immunobiology 21:286–291. Bouraoui, Y., N. Ben Rais, Z. Elouni, et al. 2006. Evolution’s molecular forms of Prostate-Specific-Antigen in serological groups of patients with prostatic pathologies. Immunobiology 21:286–291.
36.
go back to reference Oesterling, J. E. 1991. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145:907–923.PubMed Oesterling, J. E. 1991. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145:907–923.PubMed
40.
42.
go back to reference Paliouras, M., and E. P. Diamandis. 2008. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. Biol. Chem. 389:773–780. doi:10.1515/BC.2008.072.PubMedCrossRef Paliouras, M., and E. P. Diamandis. 2008. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. Biol. Chem. 389:773–780. doi:10.​1515/​BC.​2008.​072.PubMedCrossRef
43.
go back to reference Sizemore, N., S. Leung, and G. R. Strak. 1999. Activation of phosphatidylinositol 3-Kinase in response to inerleukin-1 leads to phosphorylation and activation of the NF-κB p65/RelA subnit. Mol. Cell. Biol. 19:4798–4805.PubMed Sizemore, N., S. Leung, and G. R. Strak. 1999. Activation of phosphatidylinositol 3-Kinase in response to inerleukin-1 leads to phosphorylation and activation of the NF-κB p65/RelA subnit. Mol. Cell. Biol. 19:4798–4805.PubMed
44.
go back to reference Cohen, P., H. C. Graves, D. M. Peehl, et al. 1992. Prostate specific antigen as an insulin-like growth factor binding protein-3protease found in seminal plasma. J. Clin. Endocrinol. Metab. 75:1046–1053. doi:10.1210/jc.75.4.1046.PubMedCrossRef Cohen, P., H. C. Graves, D. M. Peehl, et al. 1992. Prostate specific antigen as an insulin-like growth factor binding protein-3protease found in seminal plasma. J. Clin. Endocrinol. Metab. 75:1046–1053. doi:10.​1210/​jc.​75.​4.​1046.PubMedCrossRef
45.
go back to reference Webber, M. M., A. Waghray, and D. Bello. 1995. Prostate specific antigen, a serine protease facilitate human prostate cancer cell invasion. Clin. Cancer Res. 1:1089–1094.PubMed Webber, M. M., A. Waghray, and D. Bello. 1995. Prostate specific antigen, a serine protease facilitate human prostate cancer cell invasion. Clin. Cancer Res. 1:1089–1094.PubMed
Metadata
Title
The Profile of Prostate Epithelial Cytokines and its Impact on Sera Prostate Specific Antigen Levels
Authors
Yosra Bouraoui Mechergui
Awatef Ben Jemaa
Chekib Mezigh
Benito Fraile
Nawfel Ben Rais
Ricardo Paniagua
Mar Royuela
Ridha Oueslati
Publication date
01-06-2009
Publisher
Springer US
Published in
Inflammation / Issue 3/2009
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-009-9121-7

Other articles of this Issue 3/2009

Inflammation 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.